Gil Blum

Needham | Healthcare

Gil Blum is an analyst from Needham specializing in the Healthcare sector. Ranked #1284 out of 4535 analysts, they have issued 101 stock ratings with a success rate of 95.52% and an average return of 17.45%.

Gil Blum has a well-established track record, with 101 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 95.52% and an average return of 17.45%, underscoring their expertise and ability to identify winning opportunities for investors.

#1284

Out of 4535

101

Total Ratings

+95.52%

Success Rate

+17.45%

Average Return

Recent Ratings Analysis

ACLX

Feb 05, 2026

Target

$105.00

Current

$66.94

Performance

0.00%

Gil Blum rated ACLX as Buy on Feb 05, 2026, setting a price target of 105. Shares have remained stable near 66.94, leaving the 105 target still in play.

NRIX

Jan 29, 2026

Target

$26.00

Current

$15.95

Performance

-9.32%

On Jan 29, 2026, NRIX was given a Buy rating by Gil Blum, with a target price of 26. Despite the Buy call, shares fell from 15.95 to 15.95, challenging the optimistic stance.

SLDB

Jan 14, 2026

Target

$16.00

Current

$6.23

Performance

7.23%

SLDB received a Buy rating from Gil Blum on Jan 14, 2026, aiming for 16. Momentum has favored the Buy call, with shares climbing from 6.23 to 6.23, rewarding those who trusted the recommendation.

MREO

Jan 13, 2026

Target

$3.00

Current

$0.38

Performance

-43.18%

On Jan 13, 2026, Gil Blum published a Buy outlook on MREO, with a target of 3. Market action contradicted the Buy thesis, as shares slipped to 0.375.

AUTL

Jan 12, 2026

Target

$10.00

Current

$1.32

Performance

-12.00%

Gil Blum on Jan 12, 2026 assigned AUTL a Buy rating, with a price target of 10. The call has struggled to gain traction, with shares losing 12.00%.

RNAC

Jan 09, 2026

Target

$42.00

Current

$6.28

Performance

-23.41%

On Jan 09, 2026, Gil Blum reaffirmed RNAC with a Buy rating, targeting 42. Shares slid 23.41% despite the recommendation, highlighting downside risks.

CRSP

Dec 23, 2025

Target

$80.00

Current

$45.88

Performance

-18.74%

CRSP was rated Buy by Gil Blum on Dec 23, 2025, with a price objective of 80. This case shows how bullish projections can fail, with the stock now below 45.88.

FOLD

Dec 19, 2025

Target

$0.00

Current

$14.28

Performance

0.71%

On Dec 19, 2025, Gil Blum initiated coverage on FOLD with a Hold rating and target of null. The stock’s lack of movement around 14.28 aligned with a cautious approach.

ABSI

Dec 12, 2025

Target

$7.00

Current

$2.53

Performance

-30.49%

Gil Blum issued a Buy recommendation for ABSI on Dec 12, 2025, price target set at 7. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

GBIO

Nov 07, 2025

Target

$15.00

Current

$5.74

Performance

12.33%

On Nov 07, 2025, GBIO was evaluated by Gil Blum, who gave a Buy rating and target of 15. This case illustrates how a timely bullish rating can translate into tangible gains of 12.33%.

GERN

Nov 05, 2025

Target

$4.00

Current

$1.46

Performance

33.94%

Gil Blum rated GERN as Buy on Nov 05, 2025, setting a price target of 4. The call has proven timely, with shares rising 33.94% toward the price target of 4.

TCRX

Nov 04, 2025

Target

$6.00

Current

$0.91

Performance

-18.71%

On Nov 04, 2025, TCRX was given a Buy rating by Gil Blum, with a target price of 6. Despite the Buy call, shares fell from 0.9104 to 0.9104, challenging the optimistic stance.

FATE

Oct 27, 2025

Target

$0.00

Current

$1.05

Performance

-32.26%

FATE received a Hold rating from Gil Blum on Oct 27, 2025, aiming for null. The Hold stance proved prudent, with the market softening by 32.26%.

IMAB

Oct 24, 2025

Target

$6.00

Current

$3.48

Performance

-17.54%

On Oct 24, 2025, Gil Blum published a Buy outlook on IMAB, with a target of 6. Market action contradicted the Buy thesis, as shares slipped to 3.48.

CELC

Oct 20, 2025

Target

$70.00

Current

$104.28

Performance

47.75%

Gil Blum on Oct 20, 2025 assigned CELC a Buy rating, with a price target of 70. The Buy call aligned well with market performance, producing a gain of 47.75%.

TSHA

Oct 17, 2025

Target

$10.00

Current

$4.41

Performance

-6.57%

On Oct 17, 2025, Gil Blum reaffirmed TSHA with a Buy rating, targeting 10. Shares slid 6.57% despite the recommendation, highlighting downside risks.

ARTV

Oct 17, 2025

Target

$18.00

Current

$3.87

Performance

-35.61%

ARTV was rated Buy by Gil Blum on Oct 17, 2025, with a price objective of 18. This case shows how bullish projections can fail, with the stock now below 3.87.

RXRX

Sep 11, 2025

Target

$8.00

Current

$3.56

Performance

-26.60%

On Sep 11, 2025, Gil Blum initiated coverage on RXRX with a Buy rating and target of 8. The Buy call has yet to be validated as shares remain 4.44 away from the target.

NKTX

Aug 13, 2025

Target

$10.00

Current

$1.92

Performance

-13.12%

Gil Blum issued a Buy recommendation for NKTX on Aug 13, 2025, price target set at 10. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

SRPT

Jul 29, 2025

Target

$0.00

Current

$17.03

Performance

7.58%

On Jul 29, 2025, SRPT was evaluated by Gil Blum, who gave a Underperform rating and target of null. Investors benefited from heeding the Sell stance, avoiding a 7.58% decline.

RCKT

Jul 24, 2025

Target

$0.00

Current

$3.00

Performance

-6.54%

Gil Blum rated RCKT as Hold on Jul 24, 2025, setting a price target of null. The cautious Hold call aligned with subsequent weakness, as shares slipped 6.54%.

IMCR

Apr 10, 2025

Target

$71.00

Current

$30.92

Performance

19.75%

On Apr 10, 2025, IMCR was given a Buy rating by Gil Blum, with a target price of 71. The stock rallied 19.75% after the rating, narrowing the gap to the target of 71 and validating the bullish stance.

STTK

Mar 27, 2025

Target

$0.00

Current

$3.57

Performance

213.16%

STTK received a Hold rating from Gil Blum on Mar 27, 2025, aiming for null. Investors saw gains of 213.16% that the cautious stance didn’t fully capture.

NXTC

Aug 02, 2024

Target

$4.00

Current

$11.09

Performance

-42.24%

On Aug 02, 2024, Gil Blum published a Buy outlook on NXTC, with a target of 4. Market action contradicted the Buy thesis, as shares slipped to 11.09.

GTHX

Jun 25, 2024

Target

$6.00

Current

$7.16

Performance

225.45%

Gil Blum on Jun 25, 2024 assigned GTHX a Buy rating, with a price target of 6. The Buy call aligned well with market performance, producing a gain of 225.45%.

Frequency Asked Questions

Who is Gil Blum?

Gil Blum is an analyst from Needham specializing in the Healthcare sector.

What is Gil Blum's success rate?

Gil Blum currently has a success rate of +95.52%.

How many ratings has Gil Blum issued?

Gil Blum has issued 101 stock ratings so far.

What is the average return of Gil Blum's calls?

Their stock ratings have generated an average return of +17.45%.

What is Gil Blum's ranking?

Gil Blum is ranked #1284 out of 4535 analysts.

What types of ratings does Gil Blum give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Gil Blum?

You can follow Gil Blum by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Gil Blum?

Their latest rating was a Buy on ACLX issued on 2026-02-05.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep